These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7326239)

  • 41. Chronic toxicity of carboethoxyphthalazinohydrazine and its influence on the excretion of 5-hydroxyindoleacetic acid and the activity of 5-htp-decarboxylase in white rats.
    Chruściel M
    Br J Pharmacol Chemother; 1968 Jan; 32(1):104-12. PubMed ID: 5640168
    [No Abstract]   [Full Text] [Related]  

  • 42. A novel, inexpensive, and sensitive method for analysis of tyrosine hydroxylase activity in tissue samples.
    Blank CL; Pike R
    Life Sci; 1976 Apr; 18(8):859-65. PubMed ID: 5640
    [No Abstract]   [Full Text] [Related]  

  • 43. Interaction of L-alpha-methyl-alpha-hydrazino-3,4 dihydroxyphenylpropionic acid with dopa-decarboxylase from pig kidney.
    Borri-Voltattorni C; Minelli A; Borri P
    FEBS Lett; 1977 Mar; 75(1):277-80. PubMed ID: 852589
    [No Abstract]   [Full Text] [Related]  

  • 44. [ACTION OF CERTAIN L-DOPA/5-HTP DECARBOXYLASE INHIBITORS ON HYPOTHALAMO-HYPOPHYIAL NEUROSECRETION IN THE RAT].
    SOULAIRAC A; SOULAIRAC ML
    C R Seances Soc Biol Fil; 1964; 158():1445-7. PubMed ID: 14250544
    [No Abstract]   [Full Text] [Related]  

  • 45. Hypothalamic secretion of dopamine after inhibition of aromatic L-amino acid decarboxylase activity.
    Reymond MJ; Porter JC
    Endocrinology; 1982 Oct; 111(4):1051-6. PubMed ID: 6811255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple roles of the active site lysine of Dopa decarboxylase.
    Bertoldi M; Voltattorni CB
    Arch Biochem Biophys; 2009 Aug; 488(2):130-9. PubMed ID: 19580779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 48. [Pharmacology of several aromatic amino acid decarboxylase inhibitors].
    Uspenskiĭ AE; Dabagov NS; Skoldinov AP
    Biull Eksp Biol Med; 1978 Oct; 86(10):444-7. PubMed ID: 309344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reaction and substrate specificity of recombinant pig kidney Dopa decarboxylase under aerobic and anaerobic conditions.
    Bertoldi M; Borri Voltattorni C
    Biochim Biophys Acta; 2003 Apr; 1647(1-2):42-7. PubMed ID: 12686106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The chymotryptic phosphopyridoxyl peptide of DOPA decarboxylase from pig kidney.
    Bossa F; Martini F; Barra D; Voltattorni CB; Minelli A; Turano C
    Biochem Biophys Res Commun; 1977 Sep; 78(1):177-84. PubMed ID: 907669
    [No Abstract]   [Full Text] [Related]  

  • 51. Reaction of dopa decarboxylase with alpha-methyldopa leads to an oxidative deamination producing 3,4-dihydroxyphenylacetone, an active site directed affinity label.
    Bertoldi M; Dominici P; Moore PS; Maras B; Voltattorni CB
    Biochemistry; 1998 May; 37(18):6552-61. PubMed ID: 9572873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endogenous inhibitors of DOPA decarboxylase in rat submandibular gland.
    Hashimoto S; Ikeno T; Hasegawa J; Nagatsu T; Kuzuya H
    Arch Oral Biol; 1980; 25(3):195-9. PubMed ID: 6930957
    [No Abstract]   [Full Text] [Related]  

  • 53. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
    Huebert ND; Palfreyman MG; Haegele KD
    Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Properties of human red blood cell 1-3,4-dihydroxyphenylalanine decarboxylating activity.
    Dairman W; Christenson JG
    Eur J Pharmacol; 1973 May; 22(2):135-40. PubMed ID: 4736669
    [No Abstract]   [Full Text] [Related]  

  • 55. Aromatic-L-amino-acid decarboxylase activity in mouse pancreatic islets.
    Lindström P
    Biochim Biophys Acta; 1986 Nov; 884(2):276-81. PubMed ID: 3533158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of Dopa decarboxylase by caffeic acid and related compounds: structure-activity relationships.
    Rosei MA
    Pharmacol Res Commun; 1987 Oct; 19(10):663-71. PubMed ID: 3441482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopa decarboxylase: substrates, coenzyme, inhibitors.
    Sourkes TL
    Pharmacol Rev; 1966 Mar; 18(1):53-60. PubMed ID: 5904167
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How does L-dopa work in parkinsonism?
    Sandler M
    Lancet; 1971 Apr; 1(7703):784. PubMed ID: 4101278
    [No Abstract]   [Full Text] [Related]  

  • 60. Mechanism-based inactivation of dopa decarboxylase by serotonin.
    Bertoldi M; Moore PS; Maras B; Dominici P; Voltattorni CB
    J Biol Chem; 1996 Sep; 271(39):23954-9. PubMed ID: 8798628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.